A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects

References

• Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748.
   PubMedGoogle Scholar
• Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353(16):1652–1654.
   PubMed Web of Science ®Google Scholar
• Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):S3–8.
   PubMed Web of Science ®Google Scholar
• Carrera S, Buque A, Azkona E, et al. Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. Clin Transl Oncol. 2014;16(4):339–350.
   PubMed Web of Science ®Google Scholar
• Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32(19):2078–2099.
   PubMed Web of Science ®Google Scholar
• Ishii K, Morii N, Yamashiro H. Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy. Core Evid. 2019;14:51–70.
   PubMed Web of Science ®Google Scholar
• Hong R, Xia W, Wang L, et al. Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: an open-label, dose-escalation, phase I study. Cancer Commun (Lond). 2021;41(2):171–182.
   PubMed Web of Science ®Google Scholar
• Chung C, Lam MS. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer. Am J Health Syst Pharm. 2013;70(18):1579–1587.
   PubMed Web of Science ®Google Scholar
• Robert M, Frenel J-S, Bourbouloux E, et al. Pertuzumab for the treatment of breast cancer. Expert Rev Anticancer Ther. 2020;20(2):85–95.
   PubMed Web of Science ®Google Scholar
• Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2(2):127–137.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast cancer. N Engl J Med. 2017;377(2):122–131.
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen J, Weng Z, et al. A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action. Mol Immunol. 2020;119:48–58.
   PubMed Web of Science ®Google Scholar
• FDA:2012 Notifications. [cited 23 Feb 2018]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/2012-notifications.
   Google Scholar
• Busse A, Lüftner D. What does the pipeline promise about upcoming biosimilar antibodies in oncology? Breast Care (Basel). 2019;14(1):10–16.
   PubMed Web of Science ®Google Scholar
• Buske C, Ogura M, Kwon H-C, et al. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements. Future Oncol. 2017;13(15s):5–16.
   PubMed Web of Science ®Google Scholar
• Guideline on similar biological medicinal products. [cited 23 Oct 2014]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf.
   Google Scholar
• Fleck LM. The costs of caring: who pays? Who profits? Who panders? Hastings Cent Rep. 2006;36(3):13–17.
   PubMed Web of Science ®Google Scholar
• World Health Organization guidelines on evaluation of similar biotherapeutic products (sbps): expert committee on biological standardization Geneva, Switzerland: World Health Organization. [cited Oct 2009]. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
   Google Scholar
• Rocca A, Andreis D, Fedeli A, et al. Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy. Expert Opin Drug Metab Toxicol. 2015;11(10):1647–1663.
   PubMed Web of Science ®Google Scholar
• Genentech Inc. Perjeta™ (pertuzumab). prescribing information (USA). 2018. [cited Sep 2018]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125409s121lbl.pdf.
   Google Scholar
• Yamamoto N, Yamada Y, Fujiwara Y, et al. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol. 2009;39(4):260–266.
   PubMed Web of Science ®Google Scholar
• Kirschbrown WP, Wynne C, Kågedal M, et al. Development of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab: results from the phase Ib dose-finding study. J Clin Pharmacol. 2019;59(5):702–716.
   PubMed Web of Science ®Google Scholar
• Wang J, Niu S, Dong W, et al. A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. Expert Opin Investig Drugs. 2020;29(7):755–762.
   PubMed Web of Science ®Google Scholar
• Wang Q, Xie X, Su F, et al. A randomized controlled dose-escalation study of SSS07, a humanized rabbit anti-human TNF alpha antibody, in healthy Chinese adults. Int Immunopharmacol. 2019;75:105807.
   PubMed Web of Science ®Google Scholar
• Jamshidi A, Sabzvari A, Anjidani N, et al. A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA(R)) with the reference product (Humira(R)) in healthy volunteers. Expert Opin Investig Drugs. 2020;29(3):327–331.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li C, Liu J, et al. Safety and pharmacokinetics of a biosimilar of denosumab (KN012): phase 1 and bioequivalence study in healthy Chinese subjects. Expert Opin Investig Drugs. 2021;30(2):185–192.
   PubMed Web of Science ®Google Scholar
• von Richter O, Lemke L, Haliduola H, et al. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods. Expert Opin Biol Ther. 2019;19(10):1075–1083.
   PubMed Web of Science ®Google Scholar
• van Schie KA, Hart MH, de Groot ER, et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis. 2015;74(1):311–314.
   PubMed Web of Science ®Google Scholar
• van Schouwenburg PA, van de Stadt LA, de Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72(1):104–109.
   PubMed Web of Science ®Google Scholar
• Zhang T, Chen G, Liu C, et al. A phase I study comparing the pharmacokinetics, safety, and immunogenicity of proposed biosimilar GB242 and reference infliximab in healthy subjects. BioDrugs. 2019;33(1):93–100.
   PubMed Web of Science ®Google Scholar
• Wynne C, Schwabe C, Batra SS, et al. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin ®(EU and US) in healthy male subjects. Br J Clin Pharmacol. 2018;84(10):2352–2364.
   PubMed Web of Science ®Google Scholar